Details for New Drug Application (NDA): 021866
✉ Email this page to a colleague
NDA 021866 describes ABILIFY, which is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in seven NDAs. It is available from one supplier. There are thirty-seven patents protecting this drug and three Paragraph IV challenges. Additional details are available on the ABILIFY profile page.
The generic ingredient in ABILIFY is aripiprazole. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
The generic ingredient in ABILIFY is aripiprazole. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
Summary for 021866
| Tradename: | ABILIFY |
| Applicant: | Otsuka |
| Ingredient: | aripiprazole |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021866
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAMUSCULAR | Strength | 9.75MG/1.3ML (7.5MG/ML) | ||||
| Approval Date: | Sep 20, 2006 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
